Gyre Therapeutics announced its financial results for the second quarter ended June 30, 2025, on August 11, 2025. The company reported a net income of $1.6 million for the quarter and $5.3 million for the six months ended June 30, 2025.
ETUARY sales for the quarter were $23.5 million, compared to $25.1 million in the same period of 2024. New product launches contributed to revenue, with Etorel (nintedanib) generating $1.6 million in its first partial quarter of launch in June 2025, and Contiva (avatrombopag) generating $1.5 million in Q2 2025 after its March 2025 launch.
As of June 30, 2025, Gyre held $75.9 million in total cash, cash equivalents, short-term bank deposits, and long-term certificates of deposit, including approximately $21.3 million from the May 2025 public offering. The company reaffirmed its full-year 2025 revenue guidance of $118 million to $128 million.
In a leadership update, Dr. Han Ying stepped down as Chief Executive Officer and transitioned to Senior Vice President, Science, to oversee research and discovery. Ping Zhang, Executive Chairman, was appointed Interim Chief Executive Officer to lead day-to-day operations and strategic global expansion. Additionally, Gyre's indirect interest in Gyre Pharmaceuticals increased from 65.2% to 69.7% in the third quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.